
Clinical data supports oral treatment for atopic dermatitis
A new drug for atopic dermatitis (AD) has demonstrated a positive clinical effect and improvements in various efficacy endpoints after four weeks of treatment. The Phase Ia/IIb study was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and CCR4 surface receptor occupancy of zelnecirnon in eligible… Read More
